SLC5A2 and type 2 diabetes mellitus: The impact of combining SGLT-2 inhibitors and GLP-1 receptor agonists on cardiorenal outcomes has been evaluated in subgroup meta-analyses of CVOTs involving populations with type 2 diabetes and either established atherosclerotic CVD or multiple cardiovascular risk factors only.